277 related articles for article (PubMed ID: 32156781)
1. BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun SY
Cancer Res; 2020 Jun; 80(11):2380-2393. PubMed ID: 32156781
[TBL] [Abstract][Full Text] [Related]
2. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
4. BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC.
Shi L; Xiong Y; Hu X; Wang Z; Xie C
Int J Med Sci; 2021; 18(14):3090-3096. PubMed ID: 34400879
[TBL] [Abstract][Full Text] [Related]
5. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
8. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
[TBL] [Abstract][Full Text] [Related]
10. The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.
Liu C; Qian L; Vallega KA; Ma G; Zong D; Chen L; Wang S; Ramalingam SR; Qin Z; Sun SY
Am J Cancer Res; 2022; 12(2):779-792. PubMed ID: 35261801
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models.
Sun D; Nikonova AS; Zhang P; Deneka AY; Fitzgerald ME; Michael RE; Lee L; Lilly AC; Fisher SL; Phillips AJ; Nasveschuk CG; Proia DA; Tu Z; Golemis EA
Mol Cancer Ther; 2021 Aug; 20(8):1367-1377. PubMed ID: 34045230
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
[TBL] [Abstract][Full Text] [Related]
15. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
18. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
Zhou X; Sun T; Meng Y; Luo J; Chen J; Xia B; Zhang Z; Cheng Z; Wang X
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760217
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
Yang CY; Qin C; Bai L; Wang S
Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
[TBL] [Abstract][Full Text] [Related]
20. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]